Navigation Links
NHS Choices Launches Interactive Smoking Calculator
Date:3/11/2008

LONDON, March 11 /PRNewswire/ -- NHS Choices (http://www.nhs.uk), the digital 'front door' to the NHS launches a new smoking calculator that will allow users to see both the physical and financial cost of smoking in one simple tool.

Based on NHS accredited information, the interactive calculator (http://www.nhs.uk/Tools/Pages/Smoking.aspx) enables users to not only see the positive impact of quitting - totting up how much you could save over one to ten years - but also highlights dramatically through graphic images the negative effects of not stopping. This interactive tool is the latest addition to the NHS Choices' extensive tools library.

Notes for Editors:

NHS Choices (http://www.nhs.uk) is the online information service of the NHS that gives ordinary people the tools to make better, more informed choices about their treatments, health and wellbeing. It includes more than 80,000 pages of content, including video, interactive tools, a daily news service and lifestyle features. Users can also check and compare hospital and doctors profiles and performance on-line.

For further information, please contact NHS Choices on: +44(0)207-972-1812.


'/>"/>
SOURCE NHS Choices
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. NIH-funded Vanderbilt Research Seeks Ways to Avoid Information Overload in Health Care Choices Among Seniors
2. Congressman Walberg Awarded for Protecting Medicare Choices
3. NHS Choices Launches Tool to Assess Drinking Behaviour
4. NHS Choices Launches New Food Allergy Symptom Checker
5. IncentOne Builds More Client Flexibility, Employee Choices Into Its Health Incentive Solutions
6. NHS Choices Launches Medical News Guide to What Lies Behind the Headlines
7. NHS Choices Releases New Health A-Z Index
8. Congressman Tom Reynolds Awarded for Protecting Medicare Choices
9. Lifestyle and cancer prevention: Making choices that change cancer risk
10. Everyday Choices Can Influence Cancer Risk
11. New choices for patients: Transfusion-free medicine for Jehovahs Witnesses and transfusion-wary
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:MassMutual Recognized as One of America's Healthiest Companies 2Health News:MassMutual Recognized as One of America's Healthiest Companies 3Health News:New research identifies modifiable risk factors for heart disease 2Health News:New research identifies modifiable risk factors for heart disease 3Health News:New research identifies modifiable risk factors for heart disease 4Health News:New research identifies modifiable risk factors for heart disease 5Health News:New research identifies modifiable risk factors for heart disease 6Health News:Magnetic field measurements of the human heart at room temperature 2Health News:Magnetic field measurements of the human heart at room temperature 3Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis 2Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis 3Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis 4Health News:Spice Compounds May Stem Tumor Growth 2
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2RecoverCare and MedaSTAT USA Complete Transaction 53601 1RecoverCare and MedaSTAT USA Complete Transaction 53601 2RecoverCare and MedaSTAT USA Complete Transaction 53601 3BMP Sunstone Divests Ownership Stake in Alliance BMP Limited 53599 1BMP Sunstone Divests Ownership Stake in Alliance BMP Limited 53599 2AlphaRx and Venturepharm Announce Collaboration Agreement 53597 1AlphaRx and Venturepharm Announce Collaboration Agreement 53597 2